Praxis Precision Medicines launches with $100M and bold sights on long-evasive neurological disorders
It’s going to be the era of neuroscience, Roche CEO Bill Anderson declared on stage at the JP Morgan Healthcare Conference in January. The field, he said, had “the potential to be in the ‘20s what oncology was for the last decade.”
Five months into that decade, a new biotech is emerging from stealth mode with large investments from Blackstone and two drugs already in Phase II, one of them nearing a pivotal trial. Called Praxis Precision Medicines, since 2016 it’s raised $100 million — with Novo Holdings, Vida Ventures and Eventide also chipping in — to back a bet that, by finding the underlying cause of rare neurological diseases, they could find and treat mechanisms behind more common ones.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.